(Q24242773)

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB3

Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clini

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB3

Safety profile of ciprofloxacin during long-term therapy for pulmonary tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB3

Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB3

Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB3

Prospective comparative study of ofloxacin or ethambutol for the treatment of pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB3

Safety of an ofloxacin-based antitubercular regimen for the treatment of tuberculosis in patients with underlying chronic liver disease: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB3

A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB3

Activity of amoxicillin/clavulanate in patients with tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB3

The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB3

Levofloxacin treatment of active tuberculosis and the risk of adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB3

Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB3

The early bactericidal activity of ciprofloxacin in patients with pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB3

A multicentre study of the early bactericidal activity of anti-tuberculosis drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB3

Long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis: preliminary results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB3

Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB3

The clinical use of fluoroquinolones for the treatment of mycobacterial diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB3

Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB3

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB3

Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB3

Treatment and Outcome Analysis of 205 Patients with Multidrug-resistant Tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB3

The growing burden of tuberculosis: global trends and interactions with the HIV epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB3

An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB3

A review of efficacy studies of 6-month short-course therapy for tuberculosis among patients infected with human immunodeficiency virus: differences in study outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB3

Fluoroquinolones, tuberculosis, and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB3

Systematic reviews in health care: Assessing the quality of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB3

The global tuberculosis situation and the new control strategy of the World Health Organization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB3

Multidrug resistance in the world: the present situation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB3

Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in an immunocompetent patient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB3

Clinically significant interactions with drugs used in the treatment of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB3

Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB3

Fluoroquinolones for treating tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB3

Activity of quinolones against mycobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB3

Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis: the results up to 30 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB3

7 January 2021

Treatment of multidrug-resistant tuberculosis in Taiwan

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB3

7 January 2021

Strategies against multidrug-resistant tuberculosis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB3

7 January 2021

Controlled trial of ciprofloxacin in short-term chemotherapy for pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB3

7 January 2021

Ciprofloxacin is not a component of first-line TB

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB3

7 January 2021

Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004795.PUB3

7 January 2021

10.1002/14651858.CD004795.PUB3

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

506076

506076

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference